Beer sales, as measured by production and imports, has been steadily falling in the U.S. as consumers focus on health and trim discretionary purchases. Some have also changed how they socialize with ...

Presentation to Highlight Phase 1 REM-422 ACC Data Demonstrating 43% Overall Response Rate and Durable Responses Exceeding ...

BioArctic AB's (publ) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease ...

Eisai Co., Ltd. and Biogen Inc. announced today that results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study show that nearly 83% of early Alzheimer's disease (AD) patients ...